AbbVie Inc. Revenue & Financials

Humira's cumulative global revenues exceeded $200 billion across its commercial lifetime — more than any pharmaceutical product in history, surpassing Lipitor and Plavix by amounts that would constitute the entire revenue of a Fortune 500 company. When European biosimilar competition began in 2018 and American competition arrived in 2023, AbbVie had already spent years building out an oncology franchise through the $21 billion Pharmacyclics acquisition in 2015 and an immunology pipeline that includes Skyrizi and Rinvoq — drugs that management believes will together generate more revenue than Humira at its peak. The $63 billion Allergan acquisition in 2020 added aesthetics — Botox, Juvederm, CoolSculpting — alongside a collection of neuroscience and eye care assets. It also temporarily pushed AbbVie's net debt to approximately $83 billion. With $56.3 billion in revenue and a $320 billion market cap, AbbVie is one of the largest pharmaceutical companies on earth by valuation. AbbVie's $56.3 billion in 2024 revenue is almost identical to its 2021 figure of $56.2 billion — three years of essentially flat top-line performance that masks an extraordinary internal transformation. The $4.3 billion net income figure represents a 7.6 percent net margin on $56.3 billion in revenue — compressed by the interest expense on the debt carried from the Allergan acquisition and the ongoing costs of building out the next product generation. Management has publicly projected that Skyrizi and Rinvoq will together exceed $27 billion in revenue by 2027, a figure that would require sustained 20-plus percent annual growth from both drugs. Whether the Allergan aesthetics business, which depends heavily on consumer spending on discretionary medical procedures, can sustain growth during economic slowdowns is the variable that most analysts flag as the swing factor in whether the $320 billion valuation proves justified. AbbVie paid a $1.6 billion breakup fee and walked away. The 2015 Pharmacyclics acquisition at $21 billion secured half of Imbruvica's global profit stream, giving AbbVie its first major oncology revenue source and demonstrating that the company could execute large-scale deals.